Cargando…
Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?
Despite several clinical trials have assessed different agents in the adjuvant setting, renal cell carcinoma (RCC) still remains a disease orphan of an effective adjuvant treatment. In fact, systemic therapies targeting angiogenesis that have been observed to be effective in metastatic setting faile...
Autores principales: | Mollica, Veronica, Rizzo, Alessandro, Di Nunno, Vincenzo, Santoni, Matteo, Cheng, Liang, Lopez-Beltran, Antonio, Scarpelli, Marina, Cimadamore, Alessia, Montironi, Rodolfo, Massari, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039625/ https://www.ncbi.nlm.nih.gov/pubmed/33850792 http://dx.doi.org/10.21037/tau-20-1125 |
Ejemplares similares
-
Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review
por: Cimadamore, Alessia, et al.
Publicado: (2021) -
TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?—a narrative review
por: Rizzo, Alessandro, et al.
Publicado: (2021) -
Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now
por: Cimadamore, Alessia, et al.
Publicado: (2021) -
Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?
por: Montironi, Rodolfo, et al.
Publicado: (2021) -
Narrative review: update on immunotherapy and pathological features in patients with bladder cancer
por: Aurilio, Gaetano, et al.
Publicado: (2021)